- Home
- ELVN vs RNP Comparison
ELVN vs RNP Comparison
Compare ELVN & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELVN | RNP |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELVN | RNP |
|---|---|---|
| Price | $21.65 | $20.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $41.20 | N/A |
| AVG Volume (30 Days) | ★ 511.8K | 117.6K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $15.52 |
| 52 Week High | $25.96 | $21.27 |
Technical Indicators
Market Signals| Indicator | ELVN | RNP |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 36.97 |
| Support Level | $19.58 | $20.17 |
| Resistance Level | $21.79 | $20.67 |
| Average True Range (ATR) | 1.19 | 0.30 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 57.56 | 26.97 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.